Gain Therapeutics (GANX) Operating Income (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Operating Income of -$5.4 million for Q1 2026, down 22.52% year-over-year from -$6.9 million in Q1 2025, and down 19.87% quarter-over-quarter from -$4.5 million in Q4 2025.
Gain Therapeutics (GANX) Operating Income (2020 - 2026) Analysis & Trends
Gain Therapeutics' Operating Income history runs 7 years deep, the most recent figure standing at -$5.4 million for Q1 2026.
- In Q1 2026, Operating Income fell 22.52% year-over-year to -$5.4 million; the TTM figure through Mar 2026 stood at -$19.7 million (up 3.18% YoY), while the FY2025 annual figure was -$18.7 million, up 8.06% from the prior year.
- Operating Income for Q1 2026 stood at -$5.4 million, down from -$4.5 million in the prior quarter.
- The five-year high for Operating Income was -$3.3 million in Q1 2022, with the low at -$8.2 million in Q2 2024.
- The 5-year median for Operating Income is -$4.8 million (2022), against an average of -$5.0 million.
- The sharpest annual moves came in 2023 and 2025: Operating Income sank 59.03% in 2023, then surged 37.8% in 2025.
- Gain Therapeutics' Operating Income stood at -$4.6 million in 2022, then increased by 3.38% to -$4.4 million in 2023, then increased by 24.42% to -$3.3 million in 2024, then tumbled by 34.07% to -$4.5 million in 2025, then fell by 19.87% to -$5.4 million in 2026.
- Business Quant data shows GANX's Operating Income at -$5.4 million in Q1 2026, -$4.5 million in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | -4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.68 Mn |
| Mar 31, 2026 | -5.35 Mn |
| Dec 31, 2025 | -4.47 Mn |
| Sep 30, 2025 | -4.79 Mn |
| Jun 30, 2025 | -5.09 Mn |
| Mar 31, 2025 | -4.37 Mn |
| Dec 31, 2024 | -3.33 Mn |
| Sep 30, 2024 | -4.46 Mn |
| Jun 30, 2024 | -8.18 Mn |
| Mar 31, 2024 | -4.38 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -4.89 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -5.23 Mn |
| Dec 31, 2022 | -4.56 Mn |
| Sep 30, 2022 | -4.75 Mn |
| Jun 30, 2022 | -5.18 Mn |
| Mar 31, 2022 | -3.29 Mn |
| Dec 31, 2021 | -3.21 Mn |
| Sep 30, 2021 | -4.64 Mn |